Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases
Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological and neurodegenerative diseases, today announced it has been granted two key patents protecting its selective GPR17 (G protein-coupled receptor 17) antagonist pipeline.
Read original article on The Medical News →